NAMPT inhibitor protects ischemic neuronal injury in rat brain via antineuroinflammation, Neuroscience (2017), doi: http://dx.doi.org/10.1016/j.neuroscience. 2017.05.022 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Following cerebral ischemia, the peripheral and resident inflammatory and immune cells produce many pro-inflammatory mediators in the ischemic area, which induce neuroinflammation and impair the brain. However, the effects of NAMPT inhibitors in the neuroinflammation after ischemic brain injury remain unknown. Here, we found that FK866, a potent NAMPT inhibitor, decreased the level of TNF-α, NAMPT and IL-6 in the ischemic brain tissue at one day after middle-cerebral-artery occlusion and reperfusion (MCAO/R), improved neurological dysfunction, decreased infarct volume and neuronal loss, and inhibited microgliosis and astrogliosis at 14 days after MCAO/R. The expression of NAMPT protein was induced in Iba1-positive microglia/macrophages in the ischemia core at 14 days after MCAO/R. In vitro studies show that oxygen-glucose deprivation and recovery (OGD/R) activate microglia. Activated microglia increased the activity of NF-κB, increased the mRNA synthesis of TNF-α, NAMPT and IL-6, and increased the secretion of TNF-α, NAMPT and IL-6. On the other hand, NAMPT can act synergistically with other cytokines and activate microglia. FK866 strongly inhibited these changes and alleviated OGD/R induced activation of microglia. As such, NAMPT is a crucial determinant of cellular inflammation after cerebral ischemia. NAMPT inhibitors are novel compounds to protect neuronal injury from ischemia via anti-inflammatory effects.
INTRODUCTION
Ischemic stroke is one of the main causes of disability and death (O'Donnell et al., 2016) .
Unfortunately, therapeutic approaches for ischemic stroke are very limited (Dirnagl and Endres, 2014) . Ischemic brain injuries are not only caused by the acute ischemic attack but also by the post-ischemic inflammatory response Ma et al., 2016) . After cerebral ischemia, cells from the peripheral system, such as leukocytes, macrophages, mast cells as well as lymphocytes infiltrate the ischemic region and produce many pro-inflammatory mediators that initiate and prolong the neuroinflammtory response (Simats et al., 2016) . Resident cells, such as microglia and astrocytes (Rossi, 2015) , become activated and also play critical roles in neuroinflammation after brain ischemia Ma et al., 2016) . Neuroinflammation can initially restrict the ischemic region, but it can increase brain damage and bring many secondary complications that influence stroke outcome (Lakhan et al., 2009; Jin et al., 2010) .
Regulating neuroinflmmation has been suggested as a target for ischemic stroke therapy (Lakhan et al., 2009; Chen et al., 2014; Ma et al., 2016) .
Nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12), also named visfatin or pre-B cell colony enhancing factor (PBEF) (Samal et al., 1994; Rongvaux et al., 2002) , is the rate-limiting enzyme of the salvage pathway for nicotinamide adenine dinucleotide (NAD) synthesis. Via NAD-dependent enzymes, NAMPT is essential for cellular bioenergetics, and it participates in many important cellular processes (Garten et al., 2015) . In the brain, NAMPT is primarily expressed in neurons but not in glial cells (Zhang et al., 2010; Wang et al., 2011b; Liu et al., 2012; Zhao et al., 2013) . Growing evidence shows that NAMPT expressed in neurons has neuroprotective effects during ischemic brain injury (Zhang et al., 2010; Wang et al., 2011b; Chen et al., 2015b; Wang et al., 2016a; Wang et al., 2016b) . Knocking out NAMPT in neurons or inhibiting NAMPT injured neurons (Bi et al., 2012; Shen et al., 2013; Stein et al., 2014) .
However, many studies show that NAMPT is expressed in multiple inflammatory cells and immune cells, such as monocytes and macrophages (Presumey et al., 2013; Halvorsen et al., 2015) , neutrophils (Jia et al., 2004; Friebe et al., 2011; Malam et al., 2011) , and lymphocytes (Samal et al., 1994; Pittelli et al., 2014) . NAMPT participates in the activation of these inflammatory cells and is responsible for many inflammatory diseases (Jia et al., 2004; Malam et al., 2011; Presumey et al., 2013; Halvorsen et al., 2015) . NAMPT inhibitors, such as FK866, has potent anti-inflammatory effects, and are novel compounds for therapy of inflammatory diseases (Nowell et al., 2012; Montecucco et al., 2013; Gehrke et al., 2014; Laiguillon et al., 2014; Matsuda et al., 2014; Nencioni et al., 2014) . Research has shown that FK866 protects the mouse brain from cryoinjury and protects spinal cord injury, and both protective effects were achieved by inhibition of neuroinflammation (Esposito et al., 2012; Zhang et al., 2015) .
In addition to synthesizing NAD, NAMPT can be secreted by inflammatory cells and serve as a cytokine. The level of NAMPT in blood has been found to increase significantly in patients with inflammation-related diseases (Nowell et al., 2012; Montecucco et al., 2013; Romacho et al., 2013) . Extracellular NAMPT has been recognized as a novel cytokine in the peripheral system, which can directly activate immune and inflammatory cells via a potentially unknown receptor (Li et al., 2008; Fan et al., 2011; Audrito et al., 2015) . Most of the immune and inflammatory cells mentioned above play critical roles in neuroinflammatory responses after cerebral ischemia in the early or late phases. Thus, NAMPT may also exert as a cytokine in brain and may mediate the neuroinflammatory responses after cerebral ischemia. In addition, NAMPT may also be secreted by these cells and enhances the neuroinflammation cascades in the brain after cerebral ischemia.
As such, appropriate inhibition of NAMPT could be a novel strategy for treating cerebral ischemia.
Here, we found that the NAMPT inhibitor, FK866, significantly decreased cytokines in the brain 1 day after middle-cerebral-artery occlusion and reperfusion (MCAO/R). FK866 also strongly inhibited neuroinflammation and protected the rat brain from ischemic injury at 14 days after MCAO/R. NAMPT is inducibly expressed in Iba1-positive microglia/macrophages at 14 days after MCAO/R. In vitro studies show that TNF-α and NAMPT can activate microglia, in turn, activated microglia can secret TNF-α, NAMPT and IL-6. FK866 strongly inhibit the activation of microglia.
EXPERIMENTAL PROCEDURES

Animals, reagents and preparation of the recombinant NAMPT protein
Sprague-Dawley rats (male, 250-300 g, around 3 months old) were purchased from the Experimental Animal Center, Zhejiang Academy of Medicine Sciences (Hangzhou, China). All rats were handled in accordance with the Guide for the Care and Use of the Laboratory Animals of the National Institutes of Health. The experimental protocols were approved by the Ethics Committee of Laboratory Animal Care and Welfare, Zhejiang University School of Medicine. A total of 50 rats were used in the present study. Eighteen rats were used in the experiment of detecting NAMPT distribution. Nine and 23 rats were used in the set of experiments for evaluating the effects of FK866 at early phase and late phase of MCAO/R, respectively. FK866 (Sigma, F8557) was dissolved in dimethyl sulfoxide (DMSO, Sigma D5879) and diluted in saline before use. The recombinant TNF-α protein was purchased from MultiSciences (Lianke Biotech Co., Ltd. Hangzhou, China). The recombinant human NAMPT was prepared according to our previous report, and EI, a protein made in our laboratory, was used as a negative control (Wang et al., 2011a; Zhao et al., 2013) . The NAMPT neutralizing antibody was prepared by GL Biochem (Shanghai) Ltd.(Shanghai, China). TNF-α neutralizing antibody was purchased from the company Santa Cruz Biotechnology (sc-33639, CA, USA).
Intracerebroventricular administration of FK866
Rats were anesthetized by intraperitoneal injection of chloral hydrate (400 mg/kg) and then fixed on a stereotactic frame (SR-5, Narishige, Tokyo, Japan). A hole (1.3 mm lateral to midline and 0.6 mm posterior to bregma) was carefully drilled in the skull. Then, either 10 µl of saline, or 10 nM of FK866 in 10 µl saline was injected 5.0 mm below the skull surface within 10 min (Shi et al., 2015) . Sham-operated rats were anesthetized and a hole was drilled in the skull with no injection. The dose of FK866 was chose according to our preliminary data, which showed that 1 -10 nM FK866 in 7 µl saline decreased the NAD level in the mouse brain cortex in a dose-dependent manner, and the reduction of NAD started 1 day after injection and lasted for 10 days. In the present study, FK866 was administrated 30 min before middle cerebral artery occlusion (MCAO) operation. Here, 13 rats were administrated with saline and 13 rats were administrated with FK866. Then, 6 and 20 rats were underwent the operation of middle cerebral artery occlusion for 1 hour and reperfusion for 1day (MCAO 1h/R1d) and MCAO 1h/R14d, respectively. (Shi et al., 2015) After being anesthetized, the rats were placed on a heating pad (FHC, Bowdoinham, ME, USA) (temperature 36.5-37.5ºC). The left common carotid artery, external carotid artery (ECA) and internal carotid artery (ICA) were carefully exposed. A 4-0 monofilament nylon suture (Sunbio Biotech Co. Beijing, China) was inserted from the ECA into the ICA to block the origin of the middle cerebral artery (MCA). Changes in regional cerebral blood flow (rCBF) were recorded using a laser Doppler flowmeter (Moor Instruments, Surbiton Surrey, UK). Only rats with rCBF reduced by more than 70% during occlusion and recovered by more than 80% during reperfusion were included in the study. One hour after occlusion, the suture was withdrawn to allow reperfusion. In the sham-operated rat, the ECA was surgically isolated, but the suture was not inserted. After the operation, the rats were kept in a warm box to maintain body temperature until they wake up from anesthetization. In the present study, 15 rats were underwent sham-operation and 35 rats were performed MCAO and reperfusion.
Focal cerebral ischemia and reperfusion
Behavioral assessment and histological analysis
Neurological deficit score was evaluated at 0, 3, 6, 9, and 14 days after MCAO, according to the method reported by Longa (Longa et al., 1989) : no neurological deficit = 0, failure to extend right paw fully = 1, circling to right = 2, falling to right =3, no spontaneous locomotion and depressed level of consciousness = 4. All assessments were performed by an observer who was blinded to the treatment. All rats used for the experiments of evaluating the effects of FK866 at late phase of MCAO/R (3 sham-operated rats, 10 saline-administrated and 10 FK866-administrated MCAO/R rats) were received the assessment. The first assessment was performed when the rats had recovered from anesthesia.
Fourteen days after MCAO, the rats were euthanized with an overdose of chloral hydrate administrated by intraperitoneal injection. After rats were perfused transcardially with 4°C saline followed by 4% paraformaldehyde. The brains were removed and fixed in 4% paraformaldehyde for 1 day, and then transferred to 30% sucrose for 3 days. To measure the lesion volume and neuron density, 30-µm sections were cut using cryomicrotomy (CM1900, Leica, Wezlar, Germany (Olympus BX51, Japan). The density of the GFAP-positive cell and the optical density of the GFAP staining in the ischemic core and boundary zone were counted (cells/mm 2 ) and detected, respectively, and then were normalized to that in the contralateral area.
Preparation of brain homogenate
All 9 rats used in the experiment for evaluating the effects of FK866 at early phase of MCAO/R (3 sham-operated, 3 saline-administrated and 3 FK866-administrated MCAO 1h/R24h rats) were euthanized with an overdose of chloral hydrate administered by intraperitoneal injection and then were perfused through the heart with 4°C saline. Rat brains were then removed for homogenization. Brain tissue (100 mg) and 0.5 ml saline were added to an Eppendorf tube. The tissue was thoroughly homogenized with a homogenizer (Bio-Gen PRO200® Laboratory
Homogenizers, Thomas Scientific, NJ, USA) for 1 min on ice. The supernatant of the mixture was collected by centrifugation at 14,000 g × g for 30 min.
Cell culture
Primary rat microglia was prepared as described (Chen et al., 2015a) . In brief, a mixed glial culture was prepared from the cerebral cortex of newborn rats, and maintained in medium containing 90% MEM, 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin, for 7 days. The medium was changed every 3 days. At the 7 th day after seeding, microglia were identified as floating cells over the mixed glial culture by gentle shaking and then collected. The microglia were used 24 h after reseeding.
The rat neuron-glia mix-culture was prepared from the cerebral cortex of newborn rats, and maintained in plating medium (containing 80% high glucose DMEM, 10% fetal bovine serum, 10% horse serum, 2 mM glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin) for 24 hours.
Then, the medium was changed to feeding medium (containing 95% high glucose DMEM with 5% horse serum, 0.01% N2 and 0.04% B27). The medium was changed every 3 days thereafter.
BV2 microglial cell is a cell line derived from mouse microglia (Henn et al., 2009; Liu et al., 2014; Liu et al., 2016; Tanaka et al., 2017) . BV2 cells (Chinese Academy of Medical Sciences, Beijing, China) were cultured in high-glucose DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Sijiqing Biol., Inc., Hangzhou, Zhejiang, China).
To avoid the activation of BV2 cells and microglia, fetal bovine serum was heat inactivated for 30 min at 56°C before use.
Oxygen-Glucose Deprivation and Recovery (OGD/R)
The cultured cells were rinsed twice and incubated in Earle's solution without glucose (concentrations in mmol/L: NaCl, 117; KCl, 5.3; CaCl 2 , 1.8; NaHCO 3 , 26; MgSO 4 , 0.8; NaH 2 PO 4 , 1.0) (Zhao et al., 2013) . Then the cultures were moved into an anaerobic chamber filled with 95% N 2 and 5% CO 2 at 37°C. The control cultures were similarly washed and incubated with Earle's solution containing 5.6 mmol/L glucose and cultured in 95% air and 5% CO 2 at 37°C. At the end of OGD, the cultures were returned to the normal culture condition for the indicated time for recovery.
In all of the experiments, FK866 was applied 6 h before OGD and maintained throughout the duration of OGD for 1 h and recovery for the indicated time.
Cytokine assay
The concentrations of TNF-α, IL-6, and NAMPT in the brain tissue homogenates and in the cell culture supernatants were detected using commercial ELISA kits. TNF-α and IL-6 ELISA kits were purchased from Wuhan Boster Biological Technology, Ltd., China. The NAMPT ELISA kit was purchased from Adipogen International, Switzerland (Cat. No. AG-45A-0007EK-KI01).
ELISA results were calculated as pg/mg tissue, ng/mg protein or as percentage of the control or the OGD/R treatment.
RNA extraction and Real-Time PCR
The NAMPT, TNF-α, and IL-6-mRNA levels in the cells were measured using real-time PCR (qPCR). Briefly, after the treatments, the cell medium was removed, and the cells were washed twice with cold PBS. Total cellular RNA was extracted from the cells with the RNAiso PLUS regent (Takara Biotechnology (Dalian) Co., Ltd., China). Primer sets were obtained from Sangon Biotech, Shanghai. The sequences of primer sets for qPCR are provided in 
Morphological evaluation of the activation of microglia
After treatments, cells were photographed under the microscope. The percentage of deramified cells was then quantified according toa previous study (Lee et al., 2007) . Ramified cells are defined as cells harboring the processes, among which at least one process is longer than the diameter of the cell body. The deramified morphology representsan activation state of the primary microglia or BV2 cell is. Thus, the percentage of deramification represented the amount of the activated cells in total cells. At least 1,000 cells were counted in five separate fields for each sample.
Western blot analyses of NAMPT and NF-κB
After treatments, BV2 cells were washed twice with ice-cold PBS and then lysed at 4°C in RIPA buffer (Beyotime Biotechnology, Shanghai, China). The whole cell protein extract was obtained by centrifugation at 12,000 g at 4°C for 5 min. The cytoplasmic and nuclear protein extracts were obtained using the Nuclear 
Assessment of the cell viability
Cell viability was evaluated with the MTT assay. Briefly, MTT (0.5 mg/ml) was added to each well and the cells were incubated for 4 hours at 37ºC. Then, the culture medium were removed and 100 µl DMSO per well was added and incubated at 37ºC for 10 min. The 96-well plate was read at 570 nm using a microplate reader (Elx800, Bio-Tek Instrument). Results were reported as the percentage of control.
Statistical analysis
Data are presented as mean ± SD, and were analyzed using GraphPad Prism Software (version 6.0, GraphPad Software Inc., San Diego, CA, USA). "N" represents the number of rats used in each group, or the number of replicates for in vitro studies. In vitro studies were repeated at least twice. D'Agostino&Pearson omnibus normality test was performed to test the normality of the data. Brown-Forsythe test was performed to assess the equal variances of the data. We found all data passed normality test and equal variance test, and then we used parametric unpaired t-test and one-way ANOVA to assess the difference between means. A value of P ≤ 0.05 was considered statistically significant. Figure 1A) . A similar cellular distribution of NAMPT protein was found in the boundary zone of the cortex of rat brains at 14 days after MCAO/R ( Figure 1B) . Significantly, in the ischemic core, few NeuN-positive neurons and no GFAP-positive astrocytes were found, and NAMPT immunoreactivity was largely localized in the Iba1-positive microglia/macrophages at 14 days after MCAO/R ( Figure 1C ). In the ischemic core, 85.7 ± 3.59% of NAMPT positive cells were NAMPT and Iba-1 double positive cells ( Figure 1D ).
RESULTS
NAMPT protein expressed in
Immunohistochemical analysis showed that 14 days after MCAO/R, the number of 62.67, P ≤ 0.01, Figure 1E ]. As such, the expression of NAMPT protein can be induced in Iba1-positive microglia/macrophage in the ischemic core 14 days after MCAO/R, which represents the chronic phase of cerebral ischemia.
FK866 inhibited the activation of glial cells and alleviated brain injury 14 days after MCAO/R
To evaluate the effects of NAMPT inhibitors on brain injury and neuroinflammation after MCAO/R, FK866 (10 nM in 10 µl saline, i.c.v.) was administrated 30 min before MCAO.
Neuronal deficiency was evaluated at 0, 3, 6, 9, and 14 days after MCAO/R. Infarct volume, neuronal injury and gliosis were evaluated 14 days after MCAO/R. FK866 ameliorated neuronal deficiency at 6-14 days after MCAO/R (at 14 days after MCAO/R, 1.5 ± 0.71 for saline treatment vs 0.60 ± 0.52 for FK866 treatment; unpaired t-test, t(18) = 3.25, P ≤ 0.01, Figure 2A ), and it significantly decreased the infarct volume (9.4 ± 4.3 mm 2 for saline treatment, 3.7 ± 4.8 mm 2 for FK866 treatment; unpaired t-test, t(18) = 2.82, P ≤ 0.05, Figure 2B , 2C). Histological analysis showed that the neuronal density significantly decreased in the ischemic core and in the boundary zone, and remained intact in the contralateral area after MCAO/R ( Figure 2D, 2E Figure 2D , 2E].
Fourteen days after MCAO/R, astrocytes proliferated, and a clear glia scar formed in the boundary zone ( Figure 3A ). FK866 significantly inhibited glia scar formation ( Figure 3A) . The Iba-1 positive microglia/macrophages increased both in the ischemic core and in the boundary zone, while FK866 inhibited its increase in these two areas ( Figure 3D ). The amoeboid transformation of microglia, which reflects the activation of microglia, was observed in the ischemic core and in the boundary zone. Figure 3F ].
OGD/R increased cytokines secretion and mRNA synthesis in microglia
In BV2 cells, TNF-α, a classical inflammatory cytokine, significantly increased in the culture medium after 1 h of OGD and recovery for 2-24 h (1.17 ± 0.030 ng/mg protein for control, 0.511 ± 0.047 ng/mg protein for OGD 1h/R0h, and 2.91 ± 0.285 ng/mg protein for OGD 1h/R24h; one-way ANOVA, F(8, 18) = 42.77, P ≤ 0.01, Figure 4A ). Using Western blot analysis, we found that NAMPT protein is expressed in BV2 cells, and using ELISA, we found that NAMPT was significantly increased in the culture medium after 1 h of OGD and recovery for 12-24 h (0.20 ± 0.00 ng/mg protein for OGD 1h/R0h and control, 24.7 ± 7.33 ng/mg protein for OGD 1h/R24h; F(8, 17) = 25.84, P ≤ 0.01, Figure 4B ). IL-6, another classical inflammatory cytokine, significantly increased in the culture medium with two phases − a lower increase after 4-6 h of recovery (0.044 ± 0.027 ng/mg protein for control, 0.873 ± 0.204 ng/mg protein for OGD 1h/R6h) and a higher increase after 12-24 h of recovery (3.85 ± 0.555 ng/mg protein for OGD 1h/R24h; F(8, 16) = 66.30, P ≤ 0.01, Figure 4C ). Importantly, LDH activity in the culture medium remained unchanged after OGD 1h/R24h (100 ± 11.6 % for control vs 98.1 ± 13.4 % for OGD 1h/R24h, unpaired t-test, t(10) = 0.26, P = 0.80), indicating that the cells were not broken. These results imply that TNF-α, NAMPT, and IL-6 are secreted after OGD/R, and the secretions happened chronologically.
Using quantitative PCR, we found that the mRNA levels of TNF-α, NAMPT, and IL-6 in BV2 cells significantly increased at OGD 1h/R24h ( Figure 4D , 4E and 4F). The increase in cytokine mRNA synthesis occurs after secretion, this implies that the cells release the cytokines in storage first, and then increase synthesis of these cytokines.
FK866 inhibited OGD/R induced activation of microglia
Using an MTT assay, we found that treatment with 10 nM FK866 significantly decreased cell viability [100 ± 3.1 % for control vs 52.2 ± 5.9 % for 10 nM FK866, unpaired t-test, t(10) = 17, P ≤ 0.01], where as FK866 at 1 nM did not affect the cell viability [99.3 ± 7.6 %, t(10) = 0.20, P = 0.85]. Thus, FK866 at a concentration of 0.001-1 nM was used.
FK866 at 0.001-1 nM significantly inhibited OGD 1h/R24h-induced secretion of TNF-α [one-way ANOVA, F(9, 20) = 3.96, P ≤ 0.01, Figure 5A ], NAMPT [undetectable in the control medium, F(4, 25) = 8.74, P ≤ 0.01, Figure 5B] ; and IL-6 [F(9, 20) = 6.97, P ≤ 0.01, Figure 5C ].
Moreover, 1 nM FK866 also inhibited the increased mRNA synthesis of TNF-α, IL-6, and NAMPT that was induced by OGD/R ( Figure 5D , 5E and 5F).
After OGD/R, the p65 subunit of NF-κB in the nucleus increased at 0 h of recovery and decreased slightly at a recovery time of 3 to 6 h, it increased again at 12 h and plateaued at 24 h [one-way ANOVA, F(5, 30) = 7.13, P ≤ 0.01, Figure 6A ]. On the contrary, changes in the p65 subunit of NF-κB in the cytoplasm were opposite to that in the nucleus [F(5, 30) = 4.30, P ≤ 0.01, Figure 6B ]. This indicates nucleus translocation of the NF-κB p65 subunit, which represents the activation of NF-κB. FK866 (1 nM) significantly inhibited the increase of p65 subunit of NF-κB in the nucleus [F(2, 15) = 18.51, P ≤ 0.01, Figure 6C] , and inhibited the decrease of p65 subunit of NF-κB in the cytoplasm that was induced by OGD 1h/R24h [F(2, 15) = 7.56, P ≤ 0.01, Figure 6D ], which implies that FK866 inhibited the activation of NF-κB.
In the primary rat microglia, NAMPT protein expression is relatively low when the cells were in ramified resting state ( Figure 7A ). After OGD 1h/R24h, many primary rat microglia became deramified, and NAMPT immunofluorescent staining became stronger in the deramified cells FK866 inhibited the secretion and mRNA synthesis of cytokines, the activation of NF-κB, and the deramification of microglia induced by OGD/R. As such, FK866 possesses strong inhibitory effects on ischemic-induced activation of microglia.
NAMPT protein activates microglia and exhibits crosstalk with TNF-α α α α
To determine the roles of extracellular NAMPT that can be derived from multiple inflammatory and immune cells, a recombinant NAMPT protein was used. Without OGD/R, the application of recombinant NAMPT but not of EI (the control protein) for 24 h significantly increased the percentage of deramified cells (26.5 ± 0.74% for control， 32.3 ± 1.04% for NAMPT).
OGD/R significantly increased the percentage of deramified BV2 cells, which was further increased upon the application of the recombinant NAMPT protein [35.85 ± 1.42% for OGD 1h/R24h, 46.1±0.22% for NAMPT + OGD 1h/R24h, one-way ANOVA, F(5, 18) = 115.3, P ≤ 0.01, Figure 8A ]. OGD/R decreased viability of BV2 cells, and recombinant NAMPT, but not EI, further decreased cell viability [F(5, 30) = 17.41, P ≤ 0.01, Figure 8B ]. This implies that the treatment of NAMPT for 24h did not induce the proliferation of BV2 cells, but enhanced cell death after OGD 1h/R24h.
After OGD/R, TNF-α was released before NAMPT (from the recovery for 2 h to 24 h), while NAMPT was released later (from the recovery for 12-24 h) ( Figure 4A and 4B). Thus, we examined the relationship between NAMPT and TNF-α, and their roles in the release of IL-6, which has two release phases ( Figure 4C ). We found that TNF-α significantly increased NAMPT secretion [140 ± 4.69% of control vs control, unpaired t-test, t(4) = 11.12, P ≤ 0.01, Figure 8C ]. In turn, recombinant NAMPT, but not EI, significantly increased TNF-α secretion, and the effect of NAMPT was inhibited by a neutralizing antibody of NAMPT[t(10) = 2.69, P ≤ 0.05, Figure 8D ].
Moreover, recombinant NAMPT significantly increased the secretion of IL-6, which was inhibited by a neutralizing antibody of NAMPT. Surprisingly, the joint administration of TNF-α significantly enhanced recombinant NAMPT-induced IL-6 secretion[172 ± 36.4% of control for NAMPT, 125 ±15.7% of control for NAMPT + antibody, 288 ± 18.4% of control for NAMPT + TNF-α; one-way ANOVA, F(4, 10) = 37.67, P ≤ 0.01, Figure 8E ]. The synergistic effect between TNF-α and NAMPT may be responsible for the second higher phase of IL-6 secretion.
We further explored the roles of NAMPT in primary rat neuron-glia mix-culture. Without 
FK866 inhibited the elevation of cytokines in rat brain at 24 hours after MCAO/R
Because the direct effect of FK866 cannot last for 14 days, we hypothesize that FK866 inhibited acute neuroinflammation, and decreased neuroinflammatory cascades. Thus, with the administration of FK866 at 30 min before MCAO, we detected TNF-α, IL-6, and NAMPT protein levels in rat brain tissue homogenates at 24 hours after MCAO/R. TNF-α and NAMPT increased significantly at this time point. FK866 inhibited the increase of TNF-α [1.26 ± 0.04 pg/mg tissue for the sham, 1.85 ± 0.12 pg/mg tissue for saline treatment, 1.54 ± 0.14 pg/mg tissue for FK866 treatment, one-way ANOVA, F(2, 6) = 21.61, P ≤ 0.01, Figure 9A ]. And FK866 inhibited the increase of NAMPT [8.92 ± 0.97 pg/mg tissue for the sham, 23.2 ± 2.07 pg/mg tissue for saline treatment, 17.6 ± 3.53 pg/mg tissue for FK866 treatment, F(2, 6) = 26.30, P ≤ 0.01, Figure 9B ].
IL-6 increased slightly at 24 h after MCAO/R, and FK866 showed a tendency to reverse the increase of IL-6 ( Figure 9C ).
DISCUSSION
In the present study, we found that FK866, a potent NAMPT inhibitor, protected rat brains from cerebral ischemic injury at 14 day after MCAO and reperfusion. FK866 exerted these benefits via its anti-inflammatory effect, which is "turned on" in the acute phase of cerebral ischemia and reperfusion. In the ischemic brain, extracellular NAMPT derived from circulation and from the infiltrated inflammatory and immune cells mutually enhanced other cytokines and activated microglia. On the other hand, activated microglia increased the secretion of cytokines such as TNF-α, NAMPT and IL-6. FK866 strongly inhibited these changes and alleviated OGD/R induced activation of microglia. Lastly, induced expression of NAMPT in microglia may be responsible for the activation of microglia in the chronic phase after cerebral ischemia.
FK866 has neuroprotective effects against cerebral ischemia. Our results include amelioration of neurological deficiency, decrease of infarct volume, and alleviation of neuron loss in the ischemic area. These beneficial effects are accompanied by the inhibition of gliosis. However, the neuroprotective effect of FK866 in cerebral ischemia is opposite to previous reports, which showed that NAMPT inhibitors including FK866 decreased cellular NAD levels and exacerbated neuronal injury after ischemia (Wang et al., 2011b; Bi et al., 2012; Shen et al., 2013) . This discrepancy may be due to three differences. The first one is drug administration time. For example, Wang et al. applied FK866 at 3 days before MCAO with a dose of 4 mg/kg twice a day.
At this condition, the NAD level in the rat brain was significantly decreased and thus increased the susceptibility of neurons to ischemic injury (Wang et al., 2011b) . In comparison, we applied FK866 only 30 min before MCAO. The second difference is the concentration/dose of FK866. In primary cultured neurons, we and others found that FK866 at 100 nM but not at 10 nM or lower concentration injured neurons (Bi et al., 2012; Liu et al., 2012) . In the present study, 10 µl of 10 nM FK866 was injected into the intracerebral ventricle of rats, and thus the concentration of FK866 in brain tissues should be lower than 10 nM. This concentration of FK866 is lower than concentrations that induce injury of neurons. The third difference is the observation time. The previous studies were mainly focused on the acute phase after cerebral ischemia (normally 24 h after ischemia), and found that FK866 directly aggravated neuronal injury (Wang et al., 2011b; Bi et al., 2012; Shen et al., 2013) . However, we observed the effects of FK866 in the chronic phase (14 days after MCAO), and found that the neuroprotective effect of FK866 occurs indirectly via the inhibition of neuroinflammation after cerebral ischemia.
The anti-neuroinflammatory effect of FK866 has been reported previously (Esposito et al., 2012; Zhang et al., 2015) . Our data showed that FK866 inhibited microgliosis and astrogliosis at 14 days after MCAO. After brain ischemia, acute inflammatory responses begin immediately due to the infiltration of peripheral inflammatory and immune cells and glial activation Ma et al., 2016) .Peripheral inflammatory and immune cells that infiltrate the brain include mast cells, macrophages, neutrophils and lymphocytes (Rongvaux et al., 2002; Jia et al., 2004; Friebe et al., 2011; Malam et al., 2011; Presumey et al., 2013; Pittelli et al., 2014; Halvorsen et al., 2015) . All of these cells express and secret NAMPT, and their activation can be inhibited by NAMPT inhibitors. After infiltration, the acute inflammatory response gradually proceeds to a chronic phase that lasts weeks to several months because of the activation of microglia and astrocytes (Karve et al., 2016) . Here, our data showed that FK866 decreased the inflammatory cytokines within 24 h after ischemia and reperfusion. The decreased inflammatory cytokine level may lead to inhibition of neuroinflammation cascades. In addition, the half-life of FK866 in blood was estimated to be 7.9-76.5 h (Holen et al., 2008) , and FK866 may not last more than one week in the brain after intracerebroventricular injection. Therefore, the inhibition of microgliosis and astrogliosis by FK866 may be secondary to its anti-inflammation effects in the acute phase of ischemia and reperfusion.
Our data imply that NAMPT is a novel cytokine in the brain, and may be responsible for the development and maintenance of neuroinflammation after cerebral ischemia/reperfusion. Indeed, NAMPT has been recognized as a cytokine in the peripheral system (Sun et al., 2013) , that can be secreted by the inflammatory and immune cells that infiltrate the brain after cerebral ischemia (Li et al., 2008; Fan et al., 2011; Audrito et al., 2015) . TNF-α and IL-6 are two important pro-inflammatory cytokines that can be secreted by these cells, and are responsible for microgliasis and astrogliosis after ischemia/reperfusion (Lakhan et al., 2009; Le Thuc et al., 2015) .
Our in vitro data show that TNF-α can induce NAMPT secretion from microglia, and NAMPT can activate microglia and induce the secretion of TNF-α and IL-6 from microglia. Besides secretion from inflammatory and immune cells, extracellular NAMPT can also originate from circulation due to the broken of blood-brain-barrier after cerebral ischemia (Zhao et al., 2013) . Surprisingly, the roles of NAMPT on microglia activation can be mutually enhanced by TNF-α, which can expand and maintain neuroinflammation. In fact, in the primary rat neuron-glia mix-culture, NAMPT aggravates OGD/R-induced microglia activation, which causes the death of microglia.
The death of microglia generally means that the microglia were in an over-activation state (Lee et al., 2007) , which can exacerbate neuronal injury after ischemic injury (Zhao et al., 2013) .
In addition to the roles of extracellular NAMPT, NAMPT expression was induced in the microglia/macrophages in the ischemic core in the chronic phase of MCAO/R, which can be a cause and a result of the activation of microglia/macrophages. NF-κB is one of the most widely studied pro-inflammatory transcription factors (Taetzsch et al., 2015) , and it is an important upstream modulator of many inflammatory mediators and enzymes, including TNF-α and IL-6 (Lee et al., 2015; Shabab et al., 2016) . NF-κB signaling has also been reported as a critical mechanism that regulates microglial function and chronic neuroinflammation (Shabab et al., 2016) .
In the present study, we found that FK866 inhibited NF-κB activation, and inhibited mRNA Our results show that FK866 can indirectly protected neurons from ischemic injury via the inhibition of neuroinflammation. The minimal concentration of FK866 resulting in neuron damage is ~10 nM (Bi et al., 2012; Liu et al., 2012) , while 0.1-1 nM FK866 is efficient to inhibit the activation of microglia. Thus, the dose of FK866 can be optimized to a concentration that does not cause neuronal injury. In addition, there are multiple inflammatory and immune cells that participate in complex neuroinflammatory responses in the distinct period after brain ischemia.
Most importantly, inflammation can be beneficial because it restricts damage at the beginning of the injury. Therefore, the administration time window of FK866 needs to be optimized.
CONCLUSION
We demonstrated that NAMPT is not only responsible for the activation of microglia, but also is a novel cytokine that participate in neuroinflammation after cerebral ischemia. NAMPT inhibitors provide neuroprotective effects by alleviating neuroinflammation, and thus may be a potential therapeutic approach for cerebral ischemia and other brain diseases that involve sustained inflammation.
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